Biotalys Secures EUR 15 Million Investment for Sustainable Growth

Biotalys Gains Significant Investment through Private Placement

Biotalys NV (Euronext Brussels: BTLS), an innovative Agricultural Technology (AgTech) company, has announced receiving substantial subscription commitments totaling EUR 15 million via a private placement of new shares. This strategic financial move reflects the confidence that both existing and new investors have in Biotalys' advancements in sustainable crop protection.

Details of the Private Placement Transaction

The private placement includes the issuance of 5,300,352 new shares, amounting to approximately 16.5% of the company's pre-transaction shares. These new shares will be offered at EUR 2.83 each, representing a 10% discount based on the average price over the specified period leading up to the placement. Notable current shareholders participated in this venture, alongside the Dutch asset management firm ASR Vermogensbeheer NV, marking an essential step in Biotalys' growth journey.

Investor Perspectives on the Commitment

Ko van Nieuwenhuijzen, a Senior Portfolio Manager at ASR Vermogensbeheer, expressed admiration for Biotalys’ technology, highlighting their innovative biofungicide EVOCA™ currently pending regulatory approval. ASR's involvement signifies a commitment to investments that support both environmental sustainability and agricultural innovation.

Long-term Commitment from Existing Investors

Meanwhile, Piet Bevernage, a member of both the Executive Committee of Ackermans & van Haaren and the Biotalys Board, emphasized their ongoing support since 2019. They believe deeply in Biotalys' AGROBODY™ technology, which is pivotal to developing effective biocontrols that benefit crop protection sustainably.

Strategic Deployment of Funds

Kevin Helash, CEO of Biotalys, noted the strategic importance of this investment, stating that it will extend their cash runway as they await regulatory approvals for EVOCA. With a focus on developing new projects annually, the funding will support research and development efforts for innovative products, including the recently announced BioFun-8, aimed at enhancing fungal control.

Advancement of the R&D Pipeline

Proceeds from this private placement will primarily facilitate the regulatory process for EVOCA™ and further the development of other key products. This new influx of capital will also aid in discovering and developing additional crop protection programs and enhancing Biotalys’ competitive edge through continued platform development and intellectual property management.

Aiming for Sustainable Crop Protection Solutions

Biotalys has established a formidable pipeline of biocontrol products that are not only effective but also prioritize safety and sustainability. Their proprietary AGROBODY™ technology plays a critical role in identifying solutions to combat various crop pests and diseases. The company aims to offer alternatives to traditional chemical pesticides, reinforcing its commitment to sustainable agriculture practices.

Upcoming Changes and Projections

Looking ahead, the payment and delivery of the new shares are scheduled soon, prompting a notable increase in the company’s share capital. Following this transaction, Biotalys will enhance its share base, promoting shareholder equity and market responsiveness. Within this capital increase, current shareholders' positions will be adjusted, reflecting their ongoing investment in the company's future.

About Biotalys

Founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology), Biotalys has emerged as a frontrunner in developing environmentally friendly solutions for crop protection. Their focus on delivering safe, sustainable, and effective agricultural solutions positions them as a key player in the global effort towards sustainable food production.

Frequently Asked Questions

What was the total investment Biotalys secured through this placement?

Biotalys secured a total of EUR 15 million through the private placement.

What is the purpose of the funds raised in the placement?

The funds will support regulatory processes for products, advance R&D efforts, and enhance competitive positioning.

Who are the key investors in this initiative?

Current shareholders Ackermans & van Haaren NV and Agri Investment Fund BV participated, along with new investor ASR Vermogensbeheer NV.

What technology does Biotalys focus on for crop protection?

Biotalys utilizes its proprietary AGROBODY™ technology platform to develop innovative biocontrol solutions.

When will the new shares be delivered to investors?

The payment and delivery of the new shares are scheduled for October 16, 2024.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.